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Introduction
There is some controversy in the literature concerning
the usefulness of electroneurographic parameters such
as distal motor latency (DML), terminal latency index
(TLI),or motor conduction velocities (MCV) for the dis-
tinction between chronic inflammatory demyelinating
polyneuropathies (CIDP) and chronic demyelinating
polyneuropathy with anti-myelin-associated-glycopro-
tein (anti-MAG) antibodies. Standard electrophysiolog-
ical testing may not discriminate between CIDP and
anti-MAG polyneuropathy (anti-MAGP), Charcot-
Marie-Tooth disease (CMT1A) or hereditary neuropa-
thy with liability to pressure palsy (HNPP). In addition,
there is no specific biological marker for CIDP, and re-
sults for anti-MAG antibody or genetic testing for dele-
tion or duplication in chromosome 17p11.2 are often not
immediately available. There is efficacious treatment for
CIDP including intravenous immunoglobulin (IVIg),
corticosteroid, plasma exchange and immunosuppres-
sive drug therapy that should be given as early as possi-
ble and there are different therapeutic options with
inconsistent results for the treatment of anti-MAGP
[11–13].
Kaku et al. described 4 patients with anti-MAGP and
found in 76 % of the studied nerves a TLI ≤ 0.25, but only
in 6 % of the studied nerves in a CIDP control group [8].
Similar results were also reported by Trojaborg et al.
[17]. Recently, Katz et al. described a new variant of
CIDP, a distal acquired demyelinating symmetric neu-
ropathy (DADS) and found in 67 % of DADS a mono-
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 Abstract There is debate
whether the terminal latency index
(TLI) is a sensitive marker for
polyneuropathy with anti-myelin-
associated-glycoprotein antibodies
(anti-MAGP). We examined 6 pa-
tients with an anti-MAGP and 6 pa-
tients with a chronic inflammatory
demyelinating polyneuropathy
(CIDP). The electroneurographic
features studied were: distal com-
pound motor action potential
(CMAP), distal motor latency
(DML), motor conduction velocity
(MCV) elbow to wrist (distal
MCV), MCV axilla to elbow (proxi-
mal MCV), MCV distal/proximal,
terminal latency index (TLI), resid-
ual latency (RL), F-wave, and modi-
fied F ratio. We found significant
differences between anti-MAGP
and CIDP for DML and for RL. No
significant differences were found
for TLI and the other measures.
The TLI values were not significant
probably because our patients had
a longer duration of disease, which
supports the hypothesis of a distal
to proximal progression of conduc-
tion slowing over time. We propose
that a residual latency > 4.0 and a
distal motor latency > 7.0 are
strongly suggestive for an anti-
MAGP.
 Key words chronic
inflammatory demyelinating
polyneuropathy · anti-myelin-
associated glycoprotein
polyneuropathy · distal motor
latency · terminal latency index ·
residual latency
963
clonal gammopathy (20 of 30 patients). They could not
find any significant differences between electrophysio-
logical features, including TLI, among “classic” CIDP
with proximal and distal pattern of sensory or sensori-
motor involvement and DADS with monoclonal gam-
mopathies and anti-MAG antibodies (in 10/20 con-
firmed cases) and a more distal pattern of sensory or
sensorimotor involvement [9].
With the knowledge of these conflicting reports in
the literature, we performed this study to search for the
best electrophysiological parameter that might help to
distinguish anti-MAGP from CIDP.
Methods
 Patients
We studied 6 patients with the clinical and electrodiagnostic features
of a chronic demyelinating polyneuropathy with anti-MAG antibod-
ies who were selected for a therapeutic open-label study with ritux-
imab [13].The mean age was 61 (range 52–71) years and the mean dis-
ease duration was 7 (range 1–14) years. Six patients with a mean age
of 52 (range 40–65) years and a mean disease duration of 4.5 (range
0.25–10) years met the clinical and electrodiagnostic research criteria
of the American Academy of Neurology for idiopathic CIDP [3]. Pa-
tients with multiple myeloma or plasmocytoma,POEMS syndrome or
a motor multifocal neuropathy with a persistent conduction block
were not included.
 Electrodiagnostic studies
We performed standard motor nerve conduction studies on the ulnar
nerve using a Viking IV EMG machine (Nicolet) at skin temperatures
of 34°C. The study was performed with data from the ulnar nerve, as
it represents the best choice of a single nerve for longitudinal com-
parisons in a severe, diffuse demyelinating neuropathy for the follow-
ing reasons: 1. the ulnar nerve innervates hand muscles and, there-
fore, is easily and reproducibly measurable; 2. prolongation of its
distal latency is less likely to be confounded with an entrapment-neu-
ropathy than in the median nerve; 3. Owing to its superficial location,
supramaximal stimulation can always be achieved as opposed to the
tibial nerve, which in the popliteal fossa is relatively deeply located; 4.
it remains measurable even in severely affected patients as opposed
to the peroneal nerve, from which in our 6 patients with anti-MAG
neuropathy no CMAP was elicitable. The distal compound motor ac-
tion potential (CMAP), distal motor nerve conduction velocity
(MCV) between elbow and wrist, proximal MCV between axilla and
elbow and distal motor latency (DML) were determined. At least 16
consecutive distal F waves were elicited, and the minimum F-wave la-
tency was measured. The TLI was used to compare the wrist-to-
thenar muscle (distal segment) with the elbow-to wrist conduction
velocity. We used the formula developed by Shahani et al. [15]:
TLI = Distal conduction distance (mm)/[distal MCV(m/s) x DML
(ms)]. The TLI is the ratio between the calculated latency (dis-
tance/MCV) and the measured latency (DML). The residual latency
(RL) is a subtraction of the calculated latency from the measured la-
tency and was determined following the formula RL = DML – [distal
conduction distance/distal MCV] [5]. We calculated a ratio of distal
and proximal MCV and the modified F ratio (MFR) as recently de-
scribed by Attarian et al.: MFR = (F + DML – 2 x PML – 1)/(2 x DML)
where PML is the proximal motor latency in ms between elbow and
hypothenar muscle [1].
 Laboratory studies
All patients underwent a complete blood count, routine chemistries,
sedimentation rate, vitamin B12, antinuclear antibody, thyroid func-
tion tests, serum protein and immunofixation electrophoresis. HIV
and hepatitis panels were ordered in selected patients.Anti-MAG an-
tibodies were measured by a commercially available ELISA test
(Bühlmann Laboratories, Schönenbuch, Switzerland). In addition
bone-marrow biopsy and computed tomography of abdomen and
thorax were performed in anti-MAG positive patients. Nerve biopsies
were performed in 5 of the 6 CIDP patients revealing characteristic
findings of chronic inflammatory demyelination and in one patient
with anti-MAGP showing typical deposits of IgM in the myelin
sheath.
 Statistical analysis
Electrodiagnostic measures of patients with anti-MAG polyneuropa-
thy and CIDP were compared using nonparametric Mann-Whitney U
test. In the case of 2 tested ulnar nerves in the same patient we used
the mean value of both sides to achieve independence of the groups.
Owing to the small sample size and the unbalanced design, we left out
an analysis of variance. All tests are performed at a level of α = 0.05.
Because of the multiple interdependencies of the variables, we did not
correct the p-values of these calculations. These results therefore have
to be considered as exploratory.
Results
Comparisons between the anti-MAGP group and the
CIDP group showed significant differences between the
mean DML and RL,but not between the mean TLI (Table
1; Figs. 1–3). The DML has a median of 7.5 ms (range
4.7–13.2) in the anti-MAGP group and 3.7 ms (range
2.6–6.2) in the CIDP group (p = 0.025) and the median of
the RL in the anti-MAGP group is 4.3 ms (range 3.0–9.3)
versus 2.1 ms (range 1.33–4.14) in the CIDP group
(p = 0.025). The median of the TLI in the anti-MAGP
group is 0.31 (range 0.21–0.51) versus 0.41 (range
Table 1 Comparison of electrodiagnostic findings
Anti-MAGP CIDP p value
(n = 6 pat.) (n = 6 pat.)
DMLa 7.5 (4.7–13.2) 3.7 (2.6–6.2) 0.025
TLI 0.31 (0.21–0.51) 0.41 (0.33–0.51) n. s.
RLa 4.3 (3.0–9.3) 2.1 (1.3–4.1) 0.025
prox. MCVb 41 (28–57) 52 (23–70) n. s.
dist. MCVb 27 (17–54) 39 (25–57) n. s.
MCV dist./prox. 0.74 (0.47–1.03) 0.77 (0.56–1.69) n. s.
CMAPc 3.7 (0.6–5.9) 6.9 (1.0–33.8) n. s.
F wavea 53.3 (39.4–1000d) 32.6 (28.5–55.5) n. s.
MFR 2.6 (1.5–65.9d) 3.1 (1.3–4.1) n. s.
Median values of electrodiagnostic parameters in ulnar nerves (range)
a DML, RL, and F wave in ms
b MCV in m/s
c CMAP in mV
d F wave = 1000 ms: Test performed, but F wave not measurable
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0.33–0.51) in the CIDP group (p = n. s.). TLI ≤ 0.25 was
only met in 2 of 12 tested ulnar nerves in the anti-MAGP
group (16.7 %). Statistical comparison only of the right
ulnar nerves showed also significant differences for the
mean DML (p = 0.023) and the mean RL (p = 0.032).
There were no significant differences between the distal
MCV, the proximal MCV, the ratio proximal/distal MCV,
the CMAP, the F-wave and the modified F ratio between
these two groups. We found no asymmetry between the
6 right-sided ulnar nerves and the 6 left-sided ulnar
nerves in our anti-MAGP patients. We examined also 12
anti-MAGP peroneal nerves, but no CMAP was elic-
itable.
Discussion
CIDP and anti-MAGP are both demyelinating neu-
ropathies that differ in their pathogenesis. There are ef-
fective treatments for CIDP that should be given as early
as possible and there are different therapeutic options
for anti-MAGP with inconsistent results [11, 12]. The
pathogenesis of CIDP is still poorly understood : anti-
bodies to peripheral myelin proteins such as P0 and P2
as well to gangliosides such as GM1 can be detected in
some patients [10]. These anti-GM1 antibodies are not
specific, but high titers are most often seen with multi-
focal motor neuropathy or axonal GBS [7]. The presence
of T cells and macrophages in the biopsy specimens con-
firms the inflammatory nature of this immune-medi-
ated neuropathy [14].An enhanced synthesis of T-helper
1 cytokines resulting in damage to the blood-nerve bar-
rier and peripheral nerve myelin has been described [4].
Anti-MAGP is a chronic slowly progressive neuropa-
thy caused by monoclonal IgM-antibody against
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Fig. 1 Distal motor latency (p = 0.025; mean in the anti-MAGP group 7.8 ms, in
the CIDP group 4.1 ms)
Fig. 2 Terminal latency index (p = 0.13; mean in the anti-MAGP group 0.33, in the
CIDP group 0.41)
Fig. 3 Residual latency (p = 0.025; mean in the anti-MAGP group 5.2 ms, in the
CIDP group 2.4 ms)
Fig. 1–3 shows mean values and 95 % confidence intervals of CIDP and anti-MAGP
for DML, TLI and RL. Each star represents the mean value of one patient. In the anti-
MAGP group (n = 6) ulnar nerves were examined on both sides (12 nerves or 6
mean values), in the CIDP group (n = 6) ulnar nerves were examined on both sides
in 3 patients (6 nerves or 3 mean values) and only on one side in 3 patients (3 nerves
or 3 values)
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myelin-associated glycoprotein (MAG) in the context of
an IgM paraproteinemia [16]. Pathological studies on
nerve biopsy specimens show segmental demyelination
with deposits of IgM M-Protein and complement (C3 d,
terminal complement complex) on nerve myelin. Previ-
ous studies have shown that a reduction of anti-MAG
antibodies usually leads to an improvement of the neu-
ropathy (reviewed in 11).
CIDP has no specific biological marker, such as anti-
MAG antibody or DNA testing for CMT1A or HNPP. Al-
though these tests are diagnostic, the results are often
not readily available. Electrophysiological testing can be
helpful in the distinction between CIDP and anti-MAGP.
There is some controversy in the literature concerning
the best electrodiagnostic feature for the distinction of
CIDP from anti-MAGP and other demyelinating neu-
ropathies. Our study of the ulnar nerves showed that the
median DML and RL differed significantly between the
patients with CIDP and those with anti-MAGP as in the
study of Trojaborg et al., but not the TLI [17]. Our find-
ings show that a RL > 4.0 and a DML > 7.0 are suggestive
for an anti-MAGP although the small number of pa-
tients in our study does not permit a firm conclusion.We
have no good explanation why TLI as another measure
of distal involvement was not concordant with RL and
DML. TLI is an index and RL and DML are time para-
meters. Unlike the study of Kaku et al. where 76 % of the
tested nerves (median, ulnar, peroneal and tibial nerves)
in anti-MAGP had a TLI ≤ 0.25 or the study of Attarian
where 68 % of the tested nerves (median and ulnar
nerves) had a TLI ≤ 0.25 we found only in 16.7 % of the
studied ulnar nerves a TLI ≤ 0.25 [1, 8]. The 75 percentile
of the anti-MAGP TLI in our study was 0.4. Considering
only the ulnar nerves Attarian et al. found a TLI ≤ 0.25 in
43 % of the cases with anti-MAGP and Kaku et al. in 50 %
of the cases. Both studies found a similar mean TLI in
the ulnar nerve (Table 2).
There was no significant difference for TLI probably
because our patients had a longer duration of disease
which supports the hypothesis of a distal to proximal
progression of conduction slowing over time.Also in the
study of Cocito et al. patients with CIDP had a shorter
duration of disease which may explain their significant
lower TLIs in anti-MAGP with longer duration of dis-
ease (2, Table 2). Our anti-MAGP patients (Table 2) had
the longest duration of disease (mean duration of 84
months) compared with the published cases of Kaku
et al., Trojaborg et al., Attarian et al. and Cocito et al.
(mean duration between 34 and 60 months) [1, 2, 8, 17].
We examined also the peroneal nerves, but no CMAP
was elicitable in all anti-MAGP patients. This fact is
probably also due to the lengthy duration of disease in
our patients.
The pattern of involvement in anti-MAGP is also con-
sidered as a reflection of a length dependent process.But
the length of the ulnar nerve could not be a sufficient ex-
planation for the lack of a difference in the measured pa-
rameters between anti-MAGP and CIDP. The lack of dif-
ference in proximal conduction, F waves and modified F
ratio between anti-MAGP and CIDP is probably also due
to the duration of disease. Furthermore, the usefulness
of TLI probably depends on the clinical pattern of CIDP.
This may explain why Katz et al. found no electrodiag-
nostic differences between the distal pattern of CIDP,the
DADS variant, and the anti-MAGP with also a more dis-
tal pattern of sensory or sensorimotor involvement [9].
In accordance with Katz et al. with an inhomogeneous
group of patients with DADS and monoclonal gam-
mopathy we also found with our defined anti-MAGP
group no difference of TLI between CIDP and anti-
MAGP [9]. Dyck and Dyck recently questioned the sug-
gestion that the DADS variant should be separated from
CIDP as a specific clinical entity. They instead argued
that it is more important to distinguish patients with
neuropathy by pathophysiological processes [6]. The
course of the anti-MAGP is that of a chronic, slowly pro-
gressive disease whereas CIDP can show a fluctuating or
chronic progressive course or even remission. This may
explain differences from other studies. In this respect
our results may help to distinguish two types of de-
myelinating neuropathies that differ in their patho-
genetic mechanisms and treatments.
Table 2 DML, TLI and RL of ulnar nerve in anti-MAGP and CIDP
Ulnar nervea n age duration DML (ms) TLI RL (ms)
(years) (months)
Kaku et al. 1994
CIDP 13 ? ? ? ? ?
anti-MAGP 4 67 34 6.5 0.27 4.8
Trojaborg et al. 1995
CIDP 25 63 ? ? 0.51b 6.3b
anti-MAGP 15 62 ? ? 0.34b 9.6b
Attarian et al. 2001
CIDP 19 47 47 4.2 0.49 ?
anti-MAGP 25 65 43 5.6 0.27 ?
Cocito et al. 2001
CIDP 18 53 29 ? 0.44 ?
anti-MAGP 11 70 60 ? 0.36 ?
Radziwill et al. (present study)
CIDP 6 52 54 4.1 0.41 2.4
anti-MAGP 6 61 84 7.8 0.33 5.2
a Mean values of ulnar nerves
b Trojaborg et al. used a slightly modified definition of TLI and RL and their results
were described as a mean of the sum of median and ulnar nerve
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